Immunotherapy versus lenvatinib in hepatocellular carcinoma: the need for granular data and prospective validation
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with systemic therapies constituting the cornerstone of treatment for advanced-stage disease. While lenvatinib has been a widely used first-line agent, the advent of immunotherapy—particularly combinations...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-08-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/8/e012560.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|